Psoriatic arthritis

109 Pages·2014·1.9 MB·English

by  Chandran

O R L
OXFORD RHEUMATOLOGY LIBRARY
Psoriatic Arthritis

O R L
OXFORD RHEUMATOLOGY LIBRARY
Psoriatic Arthritis
Dafna D. Gladman , MD, FRCPC
Senior Scientist, Toronto Western Research Institute.
Centre for prognosis studies in the rheumatic diseases,
Toronto Western Hospital, Toronto, Canada;
Department of Medicine, Division of Rheumatology,
University of Toronto, Canada
Cheryl F. Rosen , MD, FRCPC
Head, Division of Dermatology,
Toronto Western Hospital Professor,
Department of Medicine,
University of Toronto, Toronto, Canada
Vinod Chandran , MBBS, MD, DM, PhD
Centre for prognosis studies in the rheumatic diseases,
Toronto Western Hospital, Toronto, Canada;
Department of Medicine, Division of Rheumatology,
University of Toronto, Canada
3
3

Great Clarendon Street, Oxford, OX2 6DP,
United Kingdom
Oxford University Press is a department of the University of Oxford.
It furthers the University’s objective of excellence in research, scholarship,
and education by publishing worldwide. Oxford is a registered trade mark of
Oxford University Press in the UK and in certain other countries
© Oxford University Press 2014
The moral rights of the authors have been asserted
Impression: 1
All rights reserved. No part of this publication may be reproduced, stored in
a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing of Oxford University Press, or as expressly permitted
by law, by licence or under terms agreed with the appropriate reprographics
rights organization. Enquiries concerning reproduction outside the scope of the
above should be sent to the Rights Department, Oxford University Press, at the
address above
You must not circulate this work in any other form
and you must impose this same condition on any acquirer
Published in the United States of America by Oxford University Press
198 Madison Avenue, New York, NY 10016, United States of America
British Library Cataloguing in Publication Data
Data available
Library of Congress Control Number: 2013957509
ISBN 978–0–19–969209–5
Printed in Great Britain by
Ashford Colour Press Ltd, Gosport, Hampshire
Oxford University Press makes no representation, express or implied, that the
drug dosages in this book are correct. Readers must therefore always check
the product information and clinical procedures with the most up-to-date
published product information and data sheets provided by the manufacturers
and the most recent codes of conduct and safety regulations. The authors and
the publishers do not accept responsibility or legal liability for any errors in the
text or for the misuse or misapplication of material in this work. Except where
otherwise stated, drug dosages and recommendations are for the non-pregnant
adult who is not breastfeeding.
Links to third party websites are provided by Oxford in good faith and
for information only. Oxford disclaims any responsibility for the materials
contained in any third party website referenced in this work.
Contents

Symbols and Abbreviations vii
1 Epidemiology 1
2 Diagnostic and classifi cation criteria 5
3 Aetiology and pathogenesis 13
4 Clinical and laboratory features of musculoskeletal manifestations 17
5 Skin and nail disease 27
6 Imaging in psoriatic arthritis 35
7 Making a diagnosis of psoriatic arthritis 51
8 Assessment of disease activity and damage in psoriatic arthritis 57
v
9 Therapeutics 69
10 Surgery 77
11 Co-morbidities 81
12 Team approach to the management of psoriatic arthritis 85
13 Prognosis 87
14 The future 93
Index 95

Symbols and Abbreviations

ACR American College of Rheumatology
ADEPT Adalimumab Eff ectiveness in Psoriatic Arthritis Trial
Apo apolipoprotein
AS ankylosing spondylitis
ASA acetylsalicylic acid
ASAS Assessment of SpondyloArthritis International Society
AxPsA axial psoriatic arthritis
BASDAI Bath Ankylosing Spondylitis Disease Activity Index
BASRI Bath Ankylosing Spondylitis Radiology Index
BSA Body Surface Area method of quantitating psoriasis
CASPAR ClASsifi cation criteria for Psoriatic ARthritis
CCP cyclic citrullinated peptide
vii
CI confi dence interval
CXCL1 growth-regulated protein α precursor; GRO- α
CPDAI Composite Psoriatic Disease Activity Index
CRP C-reactive protein
DAPSA Disease Activity Index for Psoriatic Arthritis
DAS Disease Activity Score
DIP distal interphalangeal
DLQI Dermatology Life Quality Index
DMARDs disease modifying anti-rheumatic drugs
EA enteropathic arthritis
ESSG European Spondyloarthropathy Study Group
ESR erythrocyte sedimentation rate
EULAR European League Against Rheumatism
GHS General Health Status
GRACE Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Composite Exercise
GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
GRO- α growth-regulated protein α precursor; CXCL1
GUESS Glasgow Ultrasound Enthesitis Scoring System
HADS Hospital Anxiety and Depression Scale
S HAQ Health Assessment Questionnaire
N
O HIV human immunodefi ciency virus
TI
VIA HLA human leukocyte antigen
E
R HPA hypothalamic-pituitary-adrenal
B
B
A IBD infl ammatory bowel disease
D
N ICAM-1 intercellular adhesion molecule 1
A
S ICC intraclass correlation coeffi cient
L
O
B IL interleukin
M
Y IMPACT Infl iximab Multinational Psoriatic Arthritis Controlled Trials
S
IMT carotid intima-media wall thickness
JNT joint
JSN joint space narrowing
KIR killer-cell immunoglobulin-like receptor
LDI Leeds Dactylitis Index
LS-PGA Lattice System Physician Global Assessment
M-CSF monocyte colony stimulating factor
viii MASES Maastricht Ankylosing Spondylitis Enthesitis Score
MCP metacarpophalangeal
MCP1/CCL2 monocyte chemotactic protein 1
MDA Minimal Disease Activity
MDGDA physician global assessment
MHC major histocompatibility complex
MRI magnetic resonance imaging
MTP metatarsophalangeal
MTX methotrexate
mSASSS modifi ed Stokes Ankylosing Spondylitis Spinal Score
mTSS modifi ed total Sharp score
NAFLD non-alcoholic fatty liver disease
NAPSI Nail Psoriasis Severity Index
NK natural killer cells
NPF National Psoriasis Foundation
NPF-PS National Psoriasis Foundation Psoriasis Score
NSAIDs non-steroidal anti-infl ammatory drugs
OA osteoarthritis
OMERACT Outcome Measures in Rheumatology
PAQ Psoriatic Arthritis Questionnaire
PARS Psoriatic Arthritis Ratingen Score
PASE Psoriatic Arthritis Screening Evaluation S
N
PASI Psoriasis Area and Severity Index O
TI
PASRI Psoriatic Arthritis Spondylitis Radiology Index VIA
E
PCA principal component analysis R
B
B
PGA Physician Global Assessment A
D
PGA-Ps psoriasis disease activity N
A
PIP proximal interphalangeal S
L
O
PsA psoriatic arthritis B
M
PsAJAI The Psoriatic Arthritis Joint Activity Index Y
S
PsAMRIS Psoriatic Arthritis Magnetic Resonance Imaging Scoring
PsAQoL Psoriatic Arthritis Quality of Life
PsARC PsA Response Criteria
PtGA patient global assessment
PTGDA patient global disease assessment
PUVA psoralen and ultraviolet A radiation
RA rheumatoid arthritis
RAI Ritchie Articular Index ix
RANKL receptor activator of nuclear factor κB ligand
RANTES Regulated on Activation, Normal T-cell Expressed and Secreted
RASSS Radiographic AS Spinal Score
RCT randomized controlled trial
ReA reactive arthritis
RNF ring fi nger protein
SAPHO Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis
SCORE Systematic Coronary Risk Evaluation
SD standard deviation
SF-36 Short Form-36 Health Survey
SJC Swollen Joint Count
SMR standardized mortality ratio
SNP single nucleotide polymorphism
SpA spondyloarthritis
SPARCC Spondyloarthritis Research Consortium of Canada
SPR standardized prevalence ratio
SSZ sulfasalazine
TNF tumor necrosis factor
TNFAIP3 TNF- α induced protein 3
TRAF3 TNF receptor-associated factor 3